Clinical trial enquiries:
Paradigm Biopharmaceuticals Ltd is not currently recruiting for clinical trials. All information regarding future recruitment activity will be published via our ASX announcements, on our website, and via an appropriate clinical trial registry.
Please note that Paradigm Biopharmaceuticals Ltd is unable to provide medical advice to individuals, and any matters relating to your condition or treatment must be discussed with your GP or specialist.
Subject to Therapeutic Goods Administration approval, Zilosul® may be available via the Special Access Scheme (SAS) in Australia later in 2021. Please note availability will be subject to medical and regulatory approval for each patient.
If you would like to register to be kept up to date with SAS availability, future clinical trials, market research, or other Paradigm news, please complete your details here.
General enquiries:
For general enquiries, or enquiries about our investigational products, please contact us at:
Investor Relations:
Please direct any investor relations enquiries to: